{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-184748","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2023-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.839473+00:00","generated_at":"2026-06-13T10:36:44.094528+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fulcrum licenses CAMP4's Diamond Blackfan Anemia program for up to $70M in milestones plus royalties","bullets":["Exclusive worldwide license to CAMP4's DBA program, including small molecule compounds and patent rights.","Undisclosed upfront payment; up to $35M in development/regulatory milestones and $35M in sales milestones.","Royalties on net sales: mid-single to low-double digit, subject to reductions for patent loss or generics.","Fulcrum responsible for all development and regulatory costs; CAMP4 may terminate for non-payment or patent challenges.","License expires per product/country upon later of patent expiry, regulatory exclusivity end, or 10 years after first sale."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-184748","json":"https://secwatch.observer/filing/0001193125-23-184748.json","markdown":"https://secwatch.observer/filing/0001193125-23-184748.md","text":"https://secwatch.observer/filing/0001193125-23-184748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312523184748/0001193125-23-184748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312523184748/d443448d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:36:44.094528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7ad85921e94ca4c5b7f5ae3bd6619f003857ab4","claim":"Fulcrum Therapeutics, Inc. entered into License Agreement with CAMP4 Therapeutics Corporation (effective 2023-07-05).","evidence_excerpt":"On July 5, 2023, Fulcrum Therapeutics, Inc., or Fulcrum, entered into a license agreement with CAMP4 Therapeutics Corporation, or CAMP4","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312523184748/0001193125-23-184748-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"CAMP4 Therapeutics Corporation"},{"label":"Effective","value":"2023-07-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}